In this issue:
Tandem ASCT versus autologous-allogeneic transplant
Relapse within 12-months of ASCT is prognostic for very poor outcomes
RVD therapy elicits improvements in multiple domains of QoL
Health-related QoL with thalidomide or lenalidomide-based regimes
Genetic characterisation of circulating tumour cells may offer a non-invasive method of prognostication
Revision of risk factors in MM
How well do MM cell lines model patient tumours?
Daratumumab confers reduced risk of progression in both standard- and high-risk RRMM
Conditional survival approach to assess prognosis over time
MRD negativity and maintenance therapy are associated with superior survival
Please login below to download this issue (PDF)